

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM869222

|  |                              |                       |  |
|--|------------------------------|-----------------------|--|
| <b>SUBMISSION TYPE:</b>  | NEW ASSIGNMENT               |                       |  |
| <b>NATURE OF CONVEYANCE:</b>   | RELEASE OF SECURITY INTEREST |                       |  |
| <b>CONVEYING PARTY DATA</b>  |                              |                       |  |
| <b>Name</b>  | <b>Formerly</b>              | <b>Execution Date</b> | <b>Entity Type</b>                             |
| U.S. Bank Trust Company, National Association, as successor to U.S. Bank National Association, as Collateral Agent |                              | 01/17/2024            | National Banking Association:<br>UNITED STATES |
| <b>RECEIVING PARTY DATA</b>  |                              |                       |  |
| <b>Name:</b>   | BridgeBio Pharma, Inc.       |                       |  |
| <b>Street Address:</b>   | 3160 Porter Drive, Suite 250 |                       |  |
| <b>City:</b>   | Palo Alto                    |                       |  |
| <b>State/Country:</b>  | CALIFORNIA                   |                       |  |
| <b>Postal Code:</b>  | 94304                        |                       |  |
| <b>Entity Type:</b>  | Corporation: DELAWARE        |                       |  |
| <b>Name:</b>   | Origin BioSciences, Inc.     |                       |  |
| <b>Street Address:</b>   | 3160 Porter Drive, Suite 250 |                       |  |
| <b>City:</b>   | Palo Alto                    |                       |  |
| <b>State/Country:</b>  | CALIFORNIA                   |                       |  |
| <b>Postal Code:</b>  | 94304                        |                       |  |
| <b>Entity Type:</b>  | Corporation: DELAWARE        |                       |  |
| <b>Name:</b>   | Eidos Therapeutics, Inc.     |                       |  |
| <b>Street Address:</b>   | 1800 Owens St., Suite C-1100 |                       |  |
| <b>City:</b>   | San Francisco                |                       |  |
| <b>State/Country:</b>  | CALIFORNIA                   |                       |  |
| <b>Postal Code:</b>  | 94158                        |                       |  |
| <b>Entity Type:</b>  | Corporation: DELAWARE        |                       |  |
| <b>Name:</b>   | QED Therapeutics, Inc.       |                       |  |
| <b>Street Address:</b>   | 3160 Porter Drive, Suite 250 |                       |  |
| <b>City:</b>   | Palo Alto                    |                       |  |
| <b>State/Country:</b>  | CALIFORNIA                   |                       |  |
| <b>Postal Code:</b>  | 94304                        |                       |  |
| <b>Entity Type:</b>  | Corporation: DELAWARE        |                       |  |
| <b>Name:</b>   | Adrenas Therapeutics, Inc.   |                       |  |

CH \$115.00 6531804

|                        |                                   |
|------------------------|-----------------------------------|
| <b>Street Address:</b> | 1001 William Moore Drive, Ste 100 |
| <b>City:</b>           | Raleigh                           |
| <b>State/Country:</b>  | NORTH CAROLINA                    |
| <b>Postal Code:</b>    | 27606                             |
| <b>Entity Type:</b>    | Corporation: DELAWARE             |
| <b>Name:</b>           | Phoenix Tissue Repair, Inc.       |
| <b>Street Address:</b> | 3160 Porter Drive, Suite 250      |
| <b>City:</b>           | Palo Alto                         |
| <b>State/Country:</b>  | CALIFORNIA                        |
| <b>Postal Code:</b>    | 94304                             |
| <b>Entity Type:</b>    | Corporation: DELAWARE             |

**PROPERTY NUMBERS Total: 4**

| Property Type               | Number  | Word Mark |
|-----------------------------|---------|-----------|
| <b>Registration Number:</b> | 6531804 | NULIBRY   |
| <b>Registration Number:</b> | 6413178 | BRIDGEBIO |
| <b>Registration Number:</b> | 6480657 | BRIDGEBIO |
| <b>Registration Number:</b> | 6541355 | TRUSELTIQ |

**CORRESPONDENCE DATA**

**Fax Number:** 4156932222  
*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*  
**Phone:** 4156932000  
**Email:** crhem@cooley.com  
**Correspondent Name:** Cooley LLP  
**Address Line 1:** 3 Embarcadero Center, 20th Floor  
**Address Line 4:** San Francisco, CALIFORNIA 94111

|                                |            |
|--------------------------------|------------|
| <b>ATTORNEY DOCKET NUMBER:</b> | 347580-104 |
| <b>NAME OF SUBMITTER:</b>      | C. Rhem    |
| <b>SIGNATURE:</b>              | /CR/       |
| <b>DATE SIGNED:</b>            | 01/18/2024 |

**Total Attachments: 6**  
source=BBIO - USB IPSA Termination#page1.tif  
source=BBIO - USB IPSA Termination#page2.tif  
source=BBIO - USB IPSA Termination#page3.tif  
source=BBIO - USB IPSA Termination#page4.tif  
source=BBIO - USB IPSA Termination#page5.tif  
source=BBIO - USB IPSA Termination#page6.tif

**TERMINATION AND RELEASE OF SECURITY INTEREST IN  
INTELLECTUAL PROPERTY**

**THIS TERMINATION AND RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY**, dated as of January 17, 2024, is made by U.S. Bank Trust Company, National Association (“U.S. Bank”), as successor to U.S. Bank National Association, in its capacity as collateral agent for the Secured Parties (the “Collateral Agent”) in favor of BridgeBio Pharma, Inc., a Delaware corporation (“Borrower”), Origin BioSciences, Inc., a Delaware corporation (“Origin”), Eidos Therapeutics, Inc. a Delaware corporation (“Eidos”), QED Therapeutics, Inc., a Delaware corporation (“QED”), Adrenas Therapeutics, Inc., a Delaware corporation (“Adrenas”), and Phoenix Tissue Repair, Inc. a Delaware corporation (“PTR”, and together with the Borrower, Origin, Eidos, QED, and Adrenas, individually and collectively, “Grantor”).

**WHEREAS**, Grantor has entered into a Loan and Security Agreement, dated as November 17, 2021 (as amended, restated, or otherwise modified from time to time, the “Loan Agreement”) with certain financial institutions party thereto (the “Lenders”), U.S. Bank, in its capacity as administrative agent, and the Collateral Agent. All capitalized terms used but not defined herein shall have the respective meanings given to them in the Loan Agreement.

**WHEREAS**, pursuant to the terms of the Loan Agreement, Grantor has granted to Collateral Agent for the benefit of the Secured Parties a security interest in all of Grantor’s right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

**WHEREAS**, pursuant to that certain Intellectual Property Security Agreement, dated as of November 17, 2021, made by Grantor in favor of the Collateral Agent for the Secured Parties, which was duly recorded on November 17, 2021 at Reel 007497, Frame 0731 and Reel 58144, Frame 0302 in the United States Patent and Trademark Office (as amended, restated, or otherwise modified from time to time, the “IP Security Agreement”), Grantor has granted to Collateral Agent for the benefit of the Secured Parties a security interest in all of Grantor’s right, title and interest, whether presently existing or hereafter acquired, in, to and under its intellectual property (the “Intellectual Property Collateral”), including the patents set forth on Exhibit A attached hereto (the “Patents”) and the trademarks set forth on Exhibit B attached hereto (the “Trademarks”); and

**WHEREAS**, the Collateral Agent has been requested to release and restore all right, title and interest in the Intellectual Property Collateral, including the Patents and the Trademarks, to the Grantor and to dissolve those liens and encumbrances on the Intellectual Property Collateral, including the Patents and Trademarks, created by the Loan Agreement and the IP Security Agreement.

**NOW, THEREFORE**, for good and valuable consideration, the receipt of which is hereby acknowledged, the Collateral Agent does hereby, in each case, without recourse, representation or warranty of any kind whatsoever and at the Grantor’s sole cost and expense, (a) terminate the liens and security interest created under the Loan Agreement and the IP Security Agreement in the Intellectual Property Collateral, including the Patents and Trademarks, (b) release its security interest in the Intellectual Property Collateral, including the Patents and Trademarks, (c) discharge any and all rights, title and interest it has in and the security interest granted to Collateral Agent in the Intellectual Property Collateral, including the Patents and Trademarks, and (d) reassign to Grantor, as applicable, any and all right, title and interest of any nature whatsoever which it may hold in or to any of the Intellectual Property Collateral, including the Patents and Trademarks.

Collateral Agent shall take all further actions, and provide to the Grantor and its respective successors, assigns or other legal representatives, such cooperation and assistance (including, without

limitation, the execution and delivery of any documents or other instruments), reasonably requested by the Grantor, and at the Grantor's sole cost and expense, to more fully and effectively effectuate the release of liens contemplated hereby. Collateral Agent authorizes Grantor or its designees to record the present Termination and Release of Security Interest in Intellectual Property with the United States Patent and Trademark Office or other applicable governmental authority at the sole expense of the Grantor. Collateral Agent hereby authorizes and requests that the United States Patent and Trademark Office or other applicable governmental authority note and record the present Termination and Release of Security Interest in Intellectual Property.

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, the Collateral Agent has caused this Termination and Release of Security Interest in Intellectual Property to be duly executed as of the date first set forth above.

**COLLATERAL AGENT:**

U.S. BANK TRUST COMPANY, NATIONAL  
ASSOCIATION, as successor to U.S. BANK  
NATIONAL ASSOCIATION

By:   
Name: Alison D.B. Nadeau  
Title: Vice President


**EXHIBIT A****Patents**

| <b>Company</b>              | <b>Title</b>  | <b>Application No.<br/>Filing Date</b> | <b>(Publication No.)<br/>Patent No. Issue<br/>Date</b> |
|-----------------------------|---|--|--|
| QED Therapeutics, Inc.      | Methods of treating cholangiocarcinoma                              | PCT/US2020/034881<br>5/28/2020         | (WO2020243273)   |
| QED Therapeutics, Inc.      | Methods of treating urothelial carcinoma                            | PCT/US2020/035140<br>5/29/2020         | (WO2020243442)   |
| QED Therapeutics, Inc.      | Methods of treating achondroplasia                                  | US63/127,576 12/18/2020                | NA   |
| QED Therapeutics, Inc.      | Methods of treating cancer  | US63/227,761 7/30/2021                 | NA   |
| Eidos Therapeutics, Inc.    | Processes for preparing AG-10, its intermediates, and salts thereof | US15/932,327 2/16/2018                 | (US20180237396)<br>US10513497<br>12/24/2019            |
| Eidos Therapeutics, Inc.    | Processes for preparing AG-10, its intermediates, and salts thereof | US16/676,931 11/7/2019                 | (US20200247756)<br>US11078162<br>8/3/2021              |
| Eidos Therapeutics, Inc.    | Processes for preparing AG-10, its intermediates, and salts thereof | US17/350,066 6/17/2021                 | NA   |
| Eidos Therapeutics, Inc.    | Methods of treating TTR amyloidosis using AG10                      | US16/361,587 3/22/2019                 | (US20190290616)<br>US11058668<br>7/13/2021             |
| Eidos Therapeutics, Inc.    | Methods of treating TTR amyloidosis using AG10                      | US17/332,359 5/27/2021                 | NA   |
| Eidos Therapeutics, Inc.    | Formulations of AG-10   | US16/542,737 8/16/2019                 | (US20200054607)  |
| Adrenas Therapeutics, Inc.  | Adeno-associated virus gene therapy for 21-hydroxylase deficiency   | US16/962,552 1/17/2019                 | (US20210277365)  |
| Phoenix Tissue Repair, Inc. | Method for preparing modified collagen outside a host cell          | US11/547,822 6/29/2007                 | (US20080086782)<br>US7932053<br>4/26/2011              |
| Phoenix Tissue Repair, Inc. | Collagen 7 and related methods                                      | US14/236,403 8/3/2021                  | (US20150011733)<br>US9676837<br>6/13/2017              |
| Phoenix Tissue Repair, Inc. | Collagen IV binding assay for the detection of collagen VII         | US14/440,958 5/6/2015                  | (US20160011219)<br>US9733263<br>8/15/2017              |

|                             |  |                         |  |
|-----------------------------|--|-------------------------|--|
| Phoenix Tissue Repair, Inc. | Collagen IV binding assay for the detection of collagen VII  | US15/646,303 7/11/2017  | (US20180011118)<br>US10921332<br>2/16/2021   |
| Phoenix Tissue Repair, Inc. | Collagen IV binding assay for the detection of collagen VII  | US17/141,586 1/5/2021   | (US20210132091)                              |
| Phoenix Tissue Repair, Inc. | Administration of recombinant collagen 7 for the treatment of age related disorders  | US15/791,577 10/24/2017 | (US20180036366)                              |
| Phoenix Tissue Repair, Inc. | Collagen 7 compositions and methods of using the same  | US16/065,512 6/22/2018  | (US20190000912)<br>US10,695,395<br>6/30/2020 |
| Phoenix Tissue Repair, Inc. | Collagen 7 compositions and methods of using the same  | US16/875,223 5/15/2020  | (US20200316158)                              |
| Phoenix Tissue Repair, Inc. | Methods of purifying collagen 7  | US16/084,998 9/14/2018  | (US20190077845)<br>US10669327<br>6/2/2020    |
| Phoenix Tissue Repair, Inc. | Recombinant C7 and methods of use  | US16/412,192 5/14/2019  | (US20190298809)                              |
| Origin Biosciences, Inc.    | Method for Obtaining Precursor Z and Use Thereof for the Production of a Means for Therapy of Human Molybdenum Cofactor Deficiency | US11/343,489 1/31/2006  | (US20070037250)<br>US7,504,095<br>3/17/2009  |
| Origin Biosciences, Inc.    | Method for Synthesizing Molybdopterin Precursor Z Derivatives  | US14/000,055 2/17/2012  | (US20140323726)<br>US9,260,462<br>2/16/2016  |

**EXHIBIT B**

**Trademarks**

| <b>Owner</b>                 | <b>Trademark</b>  | <b>Application No.<br/>/ Application<br/>Date</b> | <b>Registration<br/>No. / Issue Date</b> | <b>Status</b> |
|------------------------------|---|---|--|---------------|
| Origin<br>Biosciences, Inc.  | NULIBRY   | 90/015,984<br>6/23/2020                           | 6,531,804<br>10/19/2021                  | Registered.   |
| Bridgebio<br>Pharma, Inc.    | BRIDGEBIO   | 90/256,769<br>10/15/2020                          | 6,413,178<br>7/6/2021                    | Registered.   |
| Bridgebio<br>Pharma, Inc.    |  | 90/256,677<br>10/15/2020                          | 6,480,657<br>9/7/2021                    | Registered.   |
| QED<br>Therapeutics,<br>Inc. | TRUSELTIQ   | 90/975,538<br>10/19/2020                          | 6,541,355<br>10/26/2021                  | Registered.   |